Frankfurt - Delayed Quote EUR

PExA AB (publ) (FA0.F)

0.0135
0.0000
(0.00%)
At close: May 15 at 3:29:02 PM GMT+2
Loading Chart for FA0.F
  • Previous Close 0.0135
  • Open 0.0120
  • Bid 0.0145 x --
  • Ask 0.0300 x --
  • Day's Range 0.0120 - 0.0170
  • 52 Week Range 0.0076 - 0.0384
  • Volume 0
  • Avg. Volume 0
  • Market Cap (intraday) 1.118M
  • Beta (5Y Monthly) 1.13
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0200
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

PExA AB (publ) develops and commercializes diagnostic products in various respiratory diseases. It offers its products for asthma, tuberculosis, cystic fibrosis, lung cancer, and chronic obstructive pulmonary diseases. The company's research instrument helps lung researchers in the collection of microscopic particles and biomarkers for diseases in the small airways. It offers PExA 2.0, an instrument for the non-invasive collection of particles in exhaled air. The company also provides accessories, which include substrate surfaces and nozzles, as well as parts and service kits. It provides its products for lung research centers within the health services, academia, and pharmaceutical companies. The company was founded in 2004 and is based in Gothenburg, Sweden.

pexa.se

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: FA0.F

View More

Performance Overview: FA0.F

Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

FA0.F
0.75%
OMX Stockholm 30 Index (^OMX)
2.38%

1-Year Return

FA0.F
55.30%
OMX Stockholm 30 Index (^OMX)
3.24%

3-Year Return

FA0.F
74.77%
OMX Stockholm 30 Index (^OMX)
26.40%

5-Year Return

FA0.F
74.77%
OMX Stockholm 30 Index (^OMX)
70.21%

Compare To: FA0.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: FA0.F

View More

Valuation Measures

Annual
As of 5/14/2025
  • Market Cap

    1.07M

  • Enterprise Value

    556.16k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    11.88

  • Price/Book (mrq)

    1.04

  • Enterprise Value/Revenue

    8.41

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -51.62%

  • Return on Equity (ttm)

    -94.75%

  • Revenue (ttm)

    719.62k

  • Net Income Avi to Common (ttm)

    -10.16M

  • Diluted EPS (ttm)

    -0.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.59M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -5.55M

Research Analysis: FA0.F

View More

Company Insights: FA0.F

Research Reports: FA0.F

View More